"OncoGenex Pharmaceuticals Inc.’s new products could help mitigate the difficulty of treating tumours that rapidly adapt."
Welcome to OncoGeneX
Data Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
Phase 1 Study of OGX-427 Shows Early Evidence of Activity in Bladder Cancer
News & Events
Thursday, May 3 2012
OncoGenex Pharmaceuticals, Inc. Reports Financial Results and Reviews Clinical Development Highlights for First Quarter of 2012
Wednesday, Apr 25 2012
OncoGenex to Webcast Discussion of First Quarter 2012 Financial Results on Thursday, May 3, 2012
Tuesday, Mar 27 2012
OncoGenex Pharmaceuticals to Present at Two Upcoming Investor Conferences
OncoGenex is a biopharmaceutical company uniquely focused on cancer treatment resistance. We are committed to the development and commercialization of first-in-class, innovative therapies that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
Product Pipeline
Phase Three
Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
Information:
For PatientsFor PhysiciansFor InvestorsPhase Two
OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.
